

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/00, 31/425, 31/44		A1	(11) International Publication Number: WO 00/04890 (43) International Publication Date: 3 February 2000 (03.02.00)
(21) International Application Number:	PCT/GB99/02361		du Chesnay-Beauregard, Boîte postale 58, F-35762 Saint-Grégoire (FR).
(22) International Filing Date:	21 July 1999 (21.07.99)		(74) Agent: RUTTER, Keith; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).
(30) Priority Data:	9815871.0 21 July 1998 (21.07.98) GB 9815872.8 21 July 1998 (21.07.98) GB 9905387.8 9 March 1999 (09.03.99) GB		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicants (for all designated States except US):	SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES [FR/FR]; 6, esplanade Charles de Gaulle, F-92731 Nanterre Cedex (FR).		
(72) Inventors; and			Published
(75) Inventors/Applicants (for US only):	BRIL, Antoine, Michel, Alain [FR/FR]; SmithKline Beecham Laboratoires Pharmaceutiques, Unité de Recherche, Rue du Chesnay-Beauregard, Boîte postale 58, F-35762 Saint-Grégoire (FR). BUCKINGHAM, Robin, Edwin [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). KHANDOUDI, Nassirah [FR/FR]; SmithKline Beecham Laboratoires Pharmaceutiques, Unité de Recherche, Rue		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: USE OF GLUCOSE UPTAKE ENHANCER FOR REDUCING APOPTOSIS

(57) Abstract

A method for reducing or preventing apoptosis of differentiated cells selected from the list consisting of cardiac myocytes, pancreatic beta cells, endothelial cells and neuronal cells in the human or non-human mammal, which method comprises administration, including acute administration, of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.